# A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct06758544/  
OnCo record `nct06758544` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by Guangdong Provincial People's Hospital, now recruiting.

## Summary

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06758544 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 18 participants, started 2025-03-17 and due to reach its primary completion in 2026-09-30. Interventions recorded: Oncolytic virus VRT106; Chemotherapy. Conditions listed: Pancreatic Cancer. Primary outcome: Safety and tolerability. Pancreatic eligibility wording from the registry: "Have a clinical diagnosis of pancreatic cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06758544
- Phase: 1/2
- Setting: A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
- Sponsor: Guangdong Provincial People's Hospital
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT06758544: https://clinicaltrials.gov/study/NCT06758544

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06758544.json